Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Current Deferred Revenue (2023 - 2026)

Beta Bionics' Current Deferred Revenue history spans 4 years, with the latest figure at $1.7 million for Q1 2026.

  • On a quarterly basis, Current Deferred Revenue rose 79.66% to $1.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.7 million, a 79.66% increase, with the full-year FY2025 number at $1.6 million, up 65.81% from a year prior.
  • Current Deferred Revenue hit $1.7 million in Q1 2026 for Beta Bionics, up from $1.6 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for BBNX hit a ceiling of $1.7 million in Q1 2026 and a floor of $87000.0 in Q4 2023.
  • Historically, Current Deferred Revenue has averaged $1.1 million across 4 years, with a median of $1.1 million in 2025.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 979.31% in 2024 and later surged 65.81% in 2025.
  • Tracing BBNX's Current Deferred Revenue over 4 years: stood at $87000.0 in 2023, then skyrocketed by 979.31% to $939000.0 in 2024, then surged by 65.81% to $1.6 million in 2025, then grew by 9.51% to $1.7 million in 2026.
  • Business Quant data shows Current Deferred Revenue for BBNX at $1.7 million in Q1 2026, $1.6 million in Q4 2025, and $1.3 million in Q3 2025.